ANAVEX 3-71 Highly Effective and Disease-Modifying Against All Major Alzheimer’s Hallmarks in Preclinical Disease Model

Data Presented at 2014 Alzheimer’s Association International Conference (AAIC) New York, NY – July 14, 2014 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, has unveiled promising preclinical…